ijms-logo

Journal Browser

Journal Browser

Immunotherapy in Tumors: Treatments, Complications and Diagnostic Evaluation of Response

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 20 February 2025 | Viewed by 2246

Special Issue Editor


E-Mail Website
Guest Editor
Radiology Unit, Buon Consiglio Fatebenefratelli Hospital, 80123 Naples, Italy
Interests: oncologic imaging; CT; ultrasound; MRI; melanoma; cancer immunotherapy; head and neck cancer; sarcoma; soft tissue tumors; thyroid cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Immunotherapy is a powerful treatment of tumors by activating or suppressing the immune system. Cell-based immunotherapies are effective for many cancers. Immunotherapy research has attracted much attention due to its potential to treat various cancers. To deepen the understanding of functioning mechanism of various types of immunotherapy and immunotherapy-related complications, this Special Issue titled “Immunotherapy in Tumors: Treatments, Complications and Diagnostic Evaluation of Response” aims to collect the latest original recent articles and reviews describing the molecular aspects of Immunotherapy and complications, including but not limited to the following areas:  

  • Cancer Immunotherapy;
  • Immune checkpoint inhibitor;
  • complications;
  • potential side-effects;
  • Immune Response.

Dr. Fabio Sandomenico
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer immunotherapy
  • immune checkpoint inhibitor
  • complications
  • potential side-effects
  • immune response

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 4159 KiB  
Article
Development of Recombinant Oncolytic rVSV-mIL12-mGMCSF for Cancer Immunotherapy
by Anastasia Ryapolova, Ekaterina Minskaia, Nizami Gasanov, Vasiliy Moroz, Bogdan Krapivin, Alexander D. Egorov, Victor Laktyushkin, Sofia Zhuravleva, Maksim Nagornych, Elena Subcheva, Alexander Malogolovkin, Roman Ivanov and Alexander Karabelsky
Int. J. Mol. Sci. 2024, 25(1), 211; https://doi.org/10.3390/ijms25010211 - 22 Dec 2023
Cited by 1 | Viewed by 1782
Abstract
Anti-cancer therapy based on oncolytic viruses (OVs) is a targeted approach that takes advantage of OVs’ ability to selectively infect and replicate in tumor cells, activate the host immune response, and destroy malignant cells over healthy ones. Vesicular stomatitis virus (VSV) is known [...] Read more.
Anti-cancer therapy based on oncolytic viruses (OVs) is a targeted approach that takes advantage of OVs’ ability to selectively infect and replicate in tumor cells, activate the host immune response, and destroy malignant cells over healthy ones. Vesicular stomatitis virus (VSV) is known for its wide range of advantages: a lack of pre-existing immunity, a genome that is easily amenable to manipulation, and rapid growth to high titers in a broad range of cell lines, to name a few. VSV-induced tumor immunity can be enhanced by the delivery of immunostimulatory cytokines. The targeted cytokine delivery to tumors avoids the significant toxicity associated with systemic delivery while also boosting the immune response. To demonstrate this enhanced effect on both tumor growth and survival, a novel recombinant VSV (rVSV)-mIL12-mGMCSF, co-expressing mouse IL-12 (interleukin-12) and GM-CSF (granulocyte-macrophage colony-stimulating factor), was tested alongside rVSV-dM51-GFP (rVSV-GFP) that was injected intratumorally in a syngeneic in vivo C57BL/6 mouse model infused subcutaneously with B16-F10 melanoma cells. The pilot study tested the effect of two viral injections 4 days apart and demonstrated that treatment with the two rVSVs resulted in partial inhibition of tumor growth (TGII of around 40%) and an increased survival rate in animals from the treatment groups. The effect of the two VSVs on immune cell populations will be investigated in future in vivo studies with an optimized experimental design with multiple higher viral doses, as a lack of this information presents a limitation of this study. Full article
Show Figures

Figure 1

Back to TopTop